A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

NCT06926920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Sacituzumab Govitecan-hziy (SG)

Sponsor

Gilead Sciences